We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Role of metabolic rehabilitation-based approach in TNBC: biguanide metformin and more

    Lev M Berstein

    Dr Lev M Berstein is Chief of Laboratory of Oncoendocrinology at Petrov Research Institute of Oncology, St Petersburg, Russia. His main scientific interests include mechanisms of hormonal carcinogenesis, risk factors and approaches to prevention and treatment of hormone-associated tumors. He received several international distinctions (including INTAS grant and UICC Translational Cancer Research Fellowship), and serves as a Member of Council of Russian Endocrine Association, on the editorial boards of several peer-reviewed journals in cancer and endocrinology areas and as a reviewer for a number of well-known journals in these fields. In his bibliography are ten monographs, approximately 20 chapters and more than 150 papers. He graduated as MD from Tartu University in Estonia and received his PhD and DMS degrees in Cancer Endocrinology at the Petrov Institute in St Petersburg.

    Search for more papers by this author

    , ,
    Garik A Dashyan

    Dr Garik A Dashyan is Senior Scientific Associate of the NN Petrov Research Institute of Oncology (St Petersburg, Russia). His main areas of scientific research are the optimization of local and systemic treatment of breast cancer, pregnancy-associated cancer. He is the author of more than 50 scientific publications.

    Search for more papers by this author

    &
    Vladimir F Semiglazov

    Vladimir F Semiglazov is Doctor of Sciences, Corresponding Member of the Russian Academy of Medical Sciences. His main spheres of scientific research are pathogenesis of tumors, organization of clinical trials, and accomplishment of methods of surgical treatment of cancer, neoadjuvant and adjuvant systemic treatment of breast cancer. He is the author of more than 350 publications, including seven monographs.

    Search for more papers by this author

    Published Online:25 Oct 2011https://doi.org/10.2217/ebo.11.2
    Abstract:

    Triple-negative breast cancer (TNBC) presents one of the subtypes of breast cancer and is characterized with aggressive clinical course and close to complete insensibility to endocrine therapy. The aim of this chapter is to briefly characterize hormonal and metabolic features unique to TNBC, which together with some general rationales call for the usage of the metabolic rehabilitation approach in these circumstances. Metabolic rehabilitation is considered to be an important reserve in the prevention and treatment of mammary carcinomas, including TNBC.

    Bibliography

    • 1  Cianfrocca M , Gradishar W . New molecular classifications of breast cancer . CA Cancer J. Clin. . 59 (5) , 303 – 313 (2009) .
      MedlineGoogle Scholar
    • 2  Kwan ML , Kushi LH , Weltzien E et al. . Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors . Breast Cancer Res . 11 (3) , R31 (2009) .
      MedlineGoogle Scholar
    • 3  Yang XR , Chang-Claude J , Goode EL . et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies . J. Natl Cancer Inst . 103 (3) , 250 – 263 (2011) .
      MedlineGoogle Scholar
    • 4  Millikan RC , Newman B , Tse CK et al. Epidemiology of basal-like breast cancer . Breast Cancer Res. Treat . 109 (1) , 123 – 139 (2008) .
      MedlineGoogle Scholar
    • 5  Maiti B , Kundranda MN , Spiro TP , Daw HA . The association of metabolic syndrome with triple-negative breast cancer . Breast Cancer Res. Treat. 121 (2) , 479 – 483 (2010) .
      Medline CASGoogle Scholar
    • 6  Brunet J , Vazquez-Martin A , Colomer R , Graña-Suarez B , Martin-Castillo B , Menendez JA . BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer . Mol. Carcinog . 47 (2) , 157 – 163 (2008) .
      Medline CASGoogle Scholar
    • 7  Berstein LM . Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis . Future Oncol . 4 (1) , 23 – 39 (2008) .
      CASGoogle Scholar
    • 8  Goodwin PJ , Ennis M , Bahl M et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome . Breast Cancer Res. Treat. 114 (3) , 517 – 525 (2009) .
      Medline CASGoogle Scholar
    • 9  Dilman VM , Berstein LM , Yevtushenko TP et al. Preliminary evidence on metabolic rehabilitation of cancer patients . Arch. Geschwulstforsch . 58 (3) , 175 – 183 (1988) .
      Medline CASGoogle Scholar
    • 10  Berstein LM . Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond . Future Oncol . 6 (8) , 1313 – 1323 (2010) .
      CASGoogle Scholar
    • 11  Semiglazov VF , Semiglazov VV , Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer . Cancer 110 (2) , 244 – 254 (2007) .
      Medline CASGoogle Scholar
    • 12  Yagata H , Kajiura Y , Yamauchi H . Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy . Breast Cancer DOI: 10.1007/s12282-011-0254-9 (2011) (Epub ahead of print).
      Google Scholar
    • 13  Alexander BM , Sprott K , Farrow DA . et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer . Clin. Cancer Res. 16 (23) , 5796 – 5804 (2010) .
      Medline CASGoogle Scholar
    • 14  De Berardinisa RJ , Lum JJ , Hatzivassiliou G , Thompson CB . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation . Cell Metab. 7 (1) , 11 – 20 (2008) .
      MedlineGoogle Scholar
    • 15  Perou CM . Molecular stratification of triple-negative breast cancers . Oncologist 16 (Suppl. 1) , 61 – 70 (2011) .
      MedlineGoogle Scholar
    • 16  Hirsch HA , Iliopoulos D , Tsichlis PN , Struhl K . Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission . Cancer Res. 69, 7507–7511 (2009) .
      Medline CASGoogle Scholar
    • 17  Shu Y , Brown C , Castro RA et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics . Clin. Pharmacol. Ther. 83 (2) , 273 – 280 (2008) .
      Medline CASGoogle Scholar
    • 18  Pollak M . Insulin and insulin-like growth factor signalling in neoplasia . Nat. Rev. Cancer 8 (12) , 915 – 928 (2008) .
      Medline CASGoogle Scholar
    • 19  Dowling RJ , Zakikhani M , Fantus IG, Pollak M , Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells . Cancer Res. 67, 10804–10812 (2007) .
      MedlineGoogle Scholar
    • 20  Garwood ER , Kumar AS , Baehner FL et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer . Breast Cancer Res. Treat. . 119 , 137 – 144 (2010) .
      Medline CASGoogle Scholar
    • 21  Liu B , Fan Z , Edgerton SM et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells . Cell Cycle 8 (13) , 2031 – 2040 (2009) .
      Medline CASGoogle Scholar
    • 22  Vazquez-Martin A , Oliveras-Ferraros C , Cufí S . et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells . Oncol. Rep. 25 (1) , 135 – 140 (2011) .
      Medline CASGoogle Scholar
    • 23  Jiralerspong S , Gonzalez-Angulo AM , Hung MC . Expanding the arsenal: metformin for the treatment of triple-negative breast cancer? Cell Cycle 8 (17) , 2681 (2009) .
      MedlineGoogle Scholar
    • 24  Dowling RJ , Goodwin PJ , Stambolic V . Understanding the benefit of metformin use in cancer treatment . BMC Med. 9 (1) , 33 (2011) .
      Medline CASGoogle Scholar
    • 25  Cuzick J , Decensi A , Arun B . et al. Preventive therapy for breast cancer: a consensus statement . Lancet Oncol. 12 (5) , 496 – 503 (2011) .
      Medline CASGoogle Scholar

    Websites